Neuroscience — Revenue
Eli Lilly Neuroscience — Revenue decreased by 16.8% to $382.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 40.4%, from $272.00M to $382.00M. Over 4 years (FY 2021 to FY 2025), Neuroscience — Revenue shows a downward trend with a -7.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful commercialization, market penetration, or the launch of new therapies within the neuroscience portfolio, while a decrease may signal patent expirations, increased competition, or declining demand for legacy treatments.
Detailed definition
This metric represents the total net sales generated from pharmaceutical products specifically categorized under the neu...
Peer comparison
Comparable to segment-specific revenue reporting in other large-cap biopharmaceutical firms, often categorized under 'Specialty Pharma' or 'Neuroscience' business units.
lly_segment_neuroscience_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $512.20M | $450.20M | $470.70M | $397.70M | $389.90M | $373.20M | $385.30M | $360.50M | $387.20M | $1.77B | $363.20M | $389.10M | $339.50M | $351.80M | $393.60M | $272.00M | $344.00M | $315.70M | $459.20M | $382.00M |
| QoQ Change | — | -12.1% | +4.6% | -15.5% | -2.0% | -4.3% | +3.2% | -6.4% | +7.4% | +356.6% | -79.5% | +7.1% | -12.7% | +3.6% | +11.9% | -30.9% | +26.5% | -8.2% | +45.5% | -16.8% |
| YoY Change | — | — | — | — | -23.9% | -17.1% | -18.1% | -9.4% | -0.7% | +373.8% | -5.7% | +7.9% | -12.3% | -80.1% | +8.4% | -30.1% | +1.3% | -10.3% | +16.7% | +40.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's neuroscience — revenue?
- Eli Lilly (LLY) reported neuroscience — revenue of $382.00M in Q1 2026.
- How has Eli Lilly's neuroscience — revenue changed year-over-year?
- Eli Lilly's neuroscience — revenue increased by 40.4% year-over-year, from $272.00M to $382.00M.
- What is the long-term trend for Eli Lilly's neuroscience — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's neuroscience — revenue has grown at a -7.5% compound annual growth rate (CAGR), from $1.90B to $1.39B.
- What does neuroscience — revenue mean?
- Total sales revenue generated from the company's neuroscience-focused pharmaceutical products.